SecBot SecBot

AMPH

Amphastar Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001297184 Biotech & Drug Discovery
$25.41 +0.27 (+1.05%)
Oct 26 4:00 PM ET · prev $25.14
Market cap
$1.1B
Small cap
Consensus
Hold
0% Buy or better · 12 analysts
Median target
$21.00
−17% · range $20.00–30.00
Next earnings
Nov 9
in 14 days
1 year
+5.7%
from $24.04 · Oct 27
30 days
−7.2%
from $27.39
52-week range
$16.87–29.40
−14% from high · low May 15
Avg volume 20D
416.2K
shares / day
Short interest
4.41M
≈10.4% of shares · −11.8%
Days to cover
7.1
at average volume
Insider net
−$763.9K
0 buyers · 3 sellers · since Mar 4
New fund stakes
0
Q2 2026 13F · 3 exits
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 9, 2026
Strongest NEUTRAL Two Amphastar insiders, including the CFO and a senior EVP, sold a combined $343K in open-market sales over…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $763.9K.

  • InstitutionsMIXED

    Q2 2026: 24 added (0 new), 19 trimmed or exited.

  • AnalystsMIXED

    0 of 12 rate it Buy or better. Median target $21.00 (−17%).

  • Short sellersSTEADY

    Short interest −11.8% to 4.41M shares. 7.1 days to cover, ≈10.4% of shares.

  • TrendUPTREND

    4% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
3
exits
FundMoveSharesValue
FULLER & THALER ASSET MANAGEMENT, INC.TRIM949,238$19.2M
D. E. Shaw & Co., Inc.ADD887,048$17.9M
GOLDMAN SACHS GROUP INCADD505,360$10.2M
HRT FINANCIAL LPDOUBLED387,530$7.8M
ROYCE & ASSOCIATES LPTRIM294,758$5.9M
FIRST TRUST ADVISORS LPADD246,951$5.0M
JANE STREET GROUP, LLCADD178,734$3.6M
O'SHAUGHNESSY ASSET MANAGEMENT, LLCADD159,427$3.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Hold 0% rate it Buy or better
Strong Buy0Buy0Hold8Sell2Strong Sell2
12-month targets · 6 analysts

Price is inside the target range. Median implies −17%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 18, 2026Barclays
MAINTAIN
MAINTAINEqual-Weight
Aug 7, 2026Piper Sandler
MAINTAIN
MAINTAINNeutral
Aug 7, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Jun 29, 2026B of A Securities
DOWNGRADE
DOWNGRADEUnderperform
Jun 3, 2026Barclays
MAINTAIN
MAINTAINEqual-Weight
May 14, 2026Wells Fargo
DOWNGRADE
DOWNGRADEEqual-Weight

Insider ledger

Form 4
$0
bought · 0 insiders
$763.9K
sold · 3 insiders
DateInsiderTypeValue
Sep 21, 2026
PETERS WILLIAM J
CFO, EVP & TREASURER
SELL$103.5K
Sep 16, 2026
Zhou Rong
SENIOR EVP, PRODUCTION CENTER
EXERCISE$133.5K
Sep 16, 2026
Zhou Rong
SENIOR EVP, PRODUCTION CENTER
SELL$239.4K
Sep 2, 2026
Zhou Rong
SENIOR EVP, PRODUCTION CENTER
SELL$75.3K
Aug 11, 2026
PRINS RICHARD K
Director
SELL$161.9K
Aug 7, 2026
PETERS WILLIAM J
CFO, EVP & TREASURER
SELL$183.9K
Aug 7, 2026
PETERS WILLIAM J
CFO, EVP & TREASURER
EXERCISE$100.0K
Jul 9, 2026
Pierce Anthony T
Director
AWARD16,646 sh

Earnings setup

Estimates
Nov 9
reports in 14 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.69$0.69–$0.69+53.3%$194.8M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
4,405,038
shares short
-11.8%
vs prior settlement
7.1
days to cover
≈10.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 SEC
Two Amphastar insiders, including the CFO and a senior EVP, sold a combined $343K in open-market sales over a one-week…
CLUSTER — Impact 3/10
Sep 21, 2026 SEC
William J. Peters, an officer of Amphastar Pharmaceuticals, filed a Form 144 notice of intent to sell 4,139 shares of…
144 — Impact 2/10
Sep 21, 2026 Insider
PETERS WILLIAM J sold 4,139 shares
CFO, EVP & TREASURER @ $25.00 ($103.5K)
Sep 16, 2026 Insider
Zhou Rong acquired via exercise 10,000 shares
SENIOR EVP, PRODUCTION CENTER @ $13.35 ($133.5K)
Sep 16, 2026 Insider
Zhou Rong sold 10,000 shares
SENIOR EVP, PRODUCTION CENTER @ $23.94 ($239.4K)
Sep 8, 2026 Clinical trial readout
Results Pending: I004 (Phase 3) — Completed 78d ago
Trial: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed B
Aug 21, 2026 SEC
Institutional cluster for AMPH shows mixed conviction in Q2 2026: 12 buyers accumulated $13.1M in new positions, led…
INST-CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
FULLER & THALER ASSET — TRIM
949,238 shares ($19.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
AMPH Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Sep 8, 2026
Trial readout
Results Pending: I004 (Phase 3) — Completed 78d ago
Trial: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin…
Sep 8, 2026
Trial readout
Results Pending: I004 (Phase 3) — Completed 78d ago
Trial: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin…
Sep 1, 2026
Press release
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and…
Aug 25, 2026
Trial readout
Results Pending: I004 (Phase 3) — Completed 64d ago
Trial: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin…
Aug 11, 2026
Trial readout
Results Pending: I004 (Phase 3) — Completed 50d ago
Trial: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin…

SecBot reports

8 filings · 0 bullish · 1 bearish · 1 mixed · 6 neutral
All AMPH filing & press-release reports (8)